Comments
Drug firm Zydus Cadila on Wednesday announced that its wholly-owned subsidiary Zydus Healthcare Ltd has acquired six brands from American pharma player MSD and its subsidiaries in India.
The brands, which were acquired include Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range in the men’s health, women’s health, wound management and cardiovascular therapy segments, respectively, Zydus Cadila informed in a statement here.
Financial details of the deal were not disclosed.
The deal includes transfer of distribution and commercialisation rights and assignment of trademarks of all the six brands to Zydus Healthcare Ltd in India.
MSD's Indian arm Organon (India) Private Ltd has also transferred the distribution and commercialisation rights for Deca-Durabolin and Durabolin to Zydus for Nepal.
Sharvil Patel, Chairman, Zydus Healthcare Ltd, said: “We have a long-standing association with MSD in India and value them as a partner. The brands with their strong equity are a perfect addition and complement our core business and brands."
The move, seen as an acquisition of strategic brands, will strengthen Zydus’ portfolio in key therapeutic segments.
The acquired portfolio had clocked sales of ₹84 crore in 2015, the company statement informed.
Among other acquired brands, Multiload, an IUD device is expected to widen the offerings in women’s contraceptives. AXETEN is a well-known anti-hypertensive brand and Sicastat is used in wound management. With its large field force and wider reach, Zydus expects to make available and grow these brands significantly over the next few years.
PTI adds: Zydus Pharmaceuticals USA Inc is recalling over 16,000 bottles of Bupropion Hydrochloride tablets manufactured by Ahmedabad-based Cadila Healthcare on account of failure to meet the desired dissolution specifications.
Around 16,356 bottles of Bupropion Hydrochloride extended release tablets in the strength of 300 mg are being recalled by Zydus Pharmaceuticals USA Inc, the latest Enforcement Report of the USFDA said.
Bupropion hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder.
The voluntary ongoing nationwide recall is a class III recall, the report by United States Food & Drug Administration (USFDA) said.
As per the US health regulator, a class III recall is initiated in a “situation in which use of or exposure to a violative product is not likely to cause adverse health consequences“.
Zydus Pharmaceuticals USA Inc is the US arm of Zydus Cadila’s listed entity Cadila Healthcare.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.